Synergistic Impact of Alpha-Fetoprotein and Tumor Burden on Long-Term Outcomes Following Curative-Intent Resection of Hepatocellular Carcinoma

Introduction: The prognostic role of tumor burden score (TBS) relative to pre-operative α -fetoprotein (AFP) levels among patients undergoing curative-intent resection of HCC has not been examined. Methods: Patients who underwent curative-intent resection of HCC between 2000 and 2017 were identified...

Full description

Bibliographic Details
Main Authors: Diamantis I. Tsilimigras, J. Madison Hyer, Adrian Diaz, Fabio Bagante, Francesca Ratti, Hugo P. Marques, Olivier Soubrane, Vincent Lam, George A. Poultsides, Irinel Popescu, Sorin Alexandrescu, Guillaume Martel, Aklile Workneh, Alfredo Guglielmi, Tom Hugh, Luca Aldrighetti, Itaru Endo, Timothy M. Pawlik
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:Cancers
Subjects:
AFP
HCC
Online Access:https://www.mdpi.com/2072-6694/13/4/747
id doaj-5513c15e0107486283a9746a5b71a409
record_format Article
spelling doaj-5513c15e0107486283a9746a5b71a4092021-02-12T00:01:48ZengMDPI AGCancers2072-66942021-02-011374774710.3390/cancers13040747Synergistic Impact of Alpha-Fetoprotein and Tumor Burden on Long-Term Outcomes Following Curative-Intent Resection of Hepatocellular CarcinomaDiamantis I. Tsilimigras0J. Madison Hyer1Adrian Diaz2Fabio Bagante3Francesca Ratti4Hugo P. Marques5Olivier Soubrane6Vincent Lam7George A. Poultsides8Irinel Popescu9Sorin Alexandrescu10Guillaume Martel11Aklile Workneh12Alfredo Guglielmi13Tom Hugh14Luca Aldrighetti15Itaru Endo16Timothy M. Pawlik17Department of Surgery, Ohio State University Wexner Medical Center, Columbus, OH 43210, USADepartment of Surgery, Ohio State University Wexner Medical Center, Columbus, OH 43210, USADepartment of Surgery, Ohio State University Wexner Medical Center, Columbus, OH 43210, USADepartment of Surgery, Ohio State University Wexner Medical Center, Columbus, OH 43210, USADepartment of Surgery, Ospedale San Raffaele, 20132 Milano, ItalyDepartment of Surgery, Curry Cabral Hospital, 1069-166 Lisbon, PortugalDepartment of Hepatobiliopancreatic Surgery, APHP, Beaujon Hospital, 92110 Clichy, FranceDepartment of Surgery, Westmead Hospital, Sydney 2145, AustraliaDepartment of Surgery, Stanford University, Stanford, CA 94305, USADepartment of Surgery, Fundeni Clinical Institute, 022328 Bucharest, RomaniaDepartment of Surgery, Fundeni Clinical Institute, 022328 Bucharest, RomaniaDepartment of Surgery, University of Ottawa, Ottawa, ON K1H 8M5, CanadaDepartment of Surgery, University of Ottawa, Ottawa, ON K1H 8M5, CanadaDepartment of Surgery, University of Verona, 37134 Verona, ItalyDepartment of Surgery, School of Medicine, University of Sydney, Sydney 2006, AustraliaDepartment of Surgery, Ospedale San Raffaele, 20132 Milano, ItalyDepartment of Gastroenterological Surgery, Yokohama City University School of Medicine, Yokohama 236-0004, JapanDepartment of Surgery, Ohio State University Wexner Medical Center, Columbus, OH 43210, USAIntroduction: The prognostic role of tumor burden score (TBS) relative to pre-operative α -fetoprotein (AFP) levels among patients undergoing curative-intent resection of HCC has not been examined. Methods: Patients who underwent curative-intent resection of HCC between 2000 and 2017 were identified from a multi-institutional database. The impact of TBS on overall survival (OS) and cumulative recurrence relative to serum AFP levels was assessed. Results: Among 898 patients, 233 (25.9%) patients had low TBS, 572 (63.7%) had medium TBS and 93 (10.4%) had high TBS. Both TBS (5-year OS; low TBS: 76.9%, medium TBS: 60.9%, high TBS: 39.1%) and AFP (>400 ng/mL vs. <400 ng/mL: 48.5% vs. 66.1%) were strong predictors of outcomes (both <i>p</i> < 0.001). Lower TBS was associated with better OS among patients with both low (5-year OS, low–medium TBS: 68.0% vs. high TBS: 47.7%, <i>p</i> < 0.001) and high AFP levels (5-year OS, low–medium TBS: 53.7% vs. high TBS: not reached, <i>p </i>< 0.001). Patients with low–medium TBS/high AFP had worse OS compared with individuals with low–medium TBS/low AFP (5-year OS, 53.7% vs. 68.0%, <i>p</i> = 0.003). Similarly, patients with high TBS/high AFP had worse outcomes compared with patients with high TBS/low AFP (5-year OS, not reached vs. 47.7%, <i>p</i> = 0.015). Patients with high TBS/low AFP and low TBS/high AFP had comparable outcomes (5-year OS, 47.7% vs. 53.7%, <i>p </i>= 0.24). The positive predictive value of certain TBS groups relative to the risk of early recurrence and 5-year mortality after HCC resection increased with higher AFP levels. Conclusion: Both TBS and serum AFP were important predictors of prognosis among patients with resectable HCC. Serum AFP and TBS had a synergistic impact on prognosis following HCC resection with higher serum AFP predicting worse outcomes among patients with HCC of a certain TBS class.https://www.mdpi.com/2072-6694/13/4/747tumor burdenAFPHCCresectionsurgery
collection DOAJ
language English
format Article
sources DOAJ
author Diamantis I. Tsilimigras
J. Madison Hyer
Adrian Diaz
Fabio Bagante
Francesca Ratti
Hugo P. Marques
Olivier Soubrane
Vincent Lam
George A. Poultsides
Irinel Popescu
Sorin Alexandrescu
Guillaume Martel
Aklile Workneh
Alfredo Guglielmi
Tom Hugh
Luca Aldrighetti
Itaru Endo
Timothy M. Pawlik
spellingShingle Diamantis I. Tsilimigras
J. Madison Hyer
Adrian Diaz
Fabio Bagante
Francesca Ratti
Hugo P. Marques
Olivier Soubrane
Vincent Lam
George A. Poultsides
Irinel Popescu
Sorin Alexandrescu
Guillaume Martel
Aklile Workneh
Alfredo Guglielmi
Tom Hugh
Luca Aldrighetti
Itaru Endo
Timothy M. Pawlik
Synergistic Impact of Alpha-Fetoprotein and Tumor Burden on Long-Term Outcomes Following Curative-Intent Resection of Hepatocellular Carcinoma
Cancers
tumor burden
AFP
HCC
resection
surgery
author_facet Diamantis I. Tsilimigras
J. Madison Hyer
Adrian Diaz
Fabio Bagante
Francesca Ratti
Hugo P. Marques
Olivier Soubrane
Vincent Lam
George A. Poultsides
Irinel Popescu
Sorin Alexandrescu
Guillaume Martel
Aklile Workneh
Alfredo Guglielmi
Tom Hugh
Luca Aldrighetti
Itaru Endo
Timothy M. Pawlik
author_sort Diamantis I. Tsilimigras
title Synergistic Impact of Alpha-Fetoprotein and Tumor Burden on Long-Term Outcomes Following Curative-Intent Resection of Hepatocellular Carcinoma
title_short Synergistic Impact of Alpha-Fetoprotein and Tumor Burden on Long-Term Outcomes Following Curative-Intent Resection of Hepatocellular Carcinoma
title_full Synergistic Impact of Alpha-Fetoprotein and Tumor Burden on Long-Term Outcomes Following Curative-Intent Resection of Hepatocellular Carcinoma
title_fullStr Synergistic Impact of Alpha-Fetoprotein and Tumor Burden on Long-Term Outcomes Following Curative-Intent Resection of Hepatocellular Carcinoma
title_full_unstemmed Synergistic Impact of Alpha-Fetoprotein and Tumor Burden on Long-Term Outcomes Following Curative-Intent Resection of Hepatocellular Carcinoma
title_sort synergistic impact of alpha-fetoprotein and tumor burden on long-term outcomes following curative-intent resection of hepatocellular carcinoma
publisher MDPI AG
series Cancers
issn 2072-6694
publishDate 2021-02-01
description Introduction: The prognostic role of tumor burden score (TBS) relative to pre-operative α -fetoprotein (AFP) levels among patients undergoing curative-intent resection of HCC has not been examined. Methods: Patients who underwent curative-intent resection of HCC between 2000 and 2017 were identified from a multi-institutional database. The impact of TBS on overall survival (OS) and cumulative recurrence relative to serum AFP levels was assessed. Results: Among 898 patients, 233 (25.9%) patients had low TBS, 572 (63.7%) had medium TBS and 93 (10.4%) had high TBS. Both TBS (5-year OS; low TBS: 76.9%, medium TBS: 60.9%, high TBS: 39.1%) and AFP (>400 ng/mL vs. <400 ng/mL: 48.5% vs. 66.1%) were strong predictors of outcomes (both <i>p</i> < 0.001). Lower TBS was associated with better OS among patients with both low (5-year OS, low–medium TBS: 68.0% vs. high TBS: 47.7%, <i>p</i> < 0.001) and high AFP levels (5-year OS, low–medium TBS: 53.7% vs. high TBS: not reached, <i>p </i>< 0.001). Patients with low–medium TBS/high AFP had worse OS compared with individuals with low–medium TBS/low AFP (5-year OS, 53.7% vs. 68.0%, <i>p</i> = 0.003). Similarly, patients with high TBS/high AFP had worse outcomes compared with patients with high TBS/low AFP (5-year OS, not reached vs. 47.7%, <i>p</i> = 0.015). Patients with high TBS/low AFP and low TBS/high AFP had comparable outcomes (5-year OS, 47.7% vs. 53.7%, <i>p </i>= 0.24). The positive predictive value of certain TBS groups relative to the risk of early recurrence and 5-year mortality after HCC resection increased with higher AFP levels. Conclusion: Both TBS and serum AFP were important predictors of prognosis among patients with resectable HCC. Serum AFP and TBS had a synergistic impact on prognosis following HCC resection with higher serum AFP predicting worse outcomes among patients with HCC of a certain TBS class.
topic tumor burden
AFP
HCC
resection
surgery
url https://www.mdpi.com/2072-6694/13/4/747
work_keys_str_mv AT diamantisitsilimigras synergisticimpactofalphafetoproteinandtumorburdenonlongtermoutcomesfollowingcurativeintentresectionofhepatocellularcarcinoma
AT jmadisonhyer synergisticimpactofalphafetoproteinandtumorburdenonlongtermoutcomesfollowingcurativeintentresectionofhepatocellularcarcinoma
AT adriandiaz synergisticimpactofalphafetoproteinandtumorburdenonlongtermoutcomesfollowingcurativeintentresectionofhepatocellularcarcinoma
AT fabiobagante synergisticimpactofalphafetoproteinandtumorburdenonlongtermoutcomesfollowingcurativeintentresectionofhepatocellularcarcinoma
AT francescaratti synergisticimpactofalphafetoproteinandtumorburdenonlongtermoutcomesfollowingcurativeintentresectionofhepatocellularcarcinoma
AT hugopmarques synergisticimpactofalphafetoproteinandtumorburdenonlongtermoutcomesfollowingcurativeintentresectionofhepatocellularcarcinoma
AT oliviersoubrane synergisticimpactofalphafetoproteinandtumorburdenonlongtermoutcomesfollowingcurativeintentresectionofhepatocellularcarcinoma
AT vincentlam synergisticimpactofalphafetoproteinandtumorburdenonlongtermoutcomesfollowingcurativeintentresectionofhepatocellularcarcinoma
AT georgeapoultsides synergisticimpactofalphafetoproteinandtumorburdenonlongtermoutcomesfollowingcurativeintentresectionofhepatocellularcarcinoma
AT irinelpopescu synergisticimpactofalphafetoproteinandtumorburdenonlongtermoutcomesfollowingcurativeintentresectionofhepatocellularcarcinoma
AT sorinalexandrescu synergisticimpactofalphafetoproteinandtumorburdenonlongtermoutcomesfollowingcurativeintentresectionofhepatocellularcarcinoma
AT guillaumemartel synergisticimpactofalphafetoproteinandtumorburdenonlongtermoutcomesfollowingcurativeintentresectionofhepatocellularcarcinoma
AT aklileworkneh synergisticimpactofalphafetoproteinandtumorburdenonlongtermoutcomesfollowingcurativeintentresectionofhepatocellularcarcinoma
AT alfredoguglielmi synergisticimpactofalphafetoproteinandtumorburdenonlongtermoutcomesfollowingcurativeintentresectionofhepatocellularcarcinoma
AT tomhugh synergisticimpactofalphafetoproteinandtumorburdenonlongtermoutcomesfollowingcurativeintentresectionofhepatocellularcarcinoma
AT lucaaldrighetti synergisticimpactofalphafetoproteinandtumorburdenonlongtermoutcomesfollowingcurativeintentresectionofhepatocellularcarcinoma
AT itaruendo synergisticimpactofalphafetoproteinandtumorburdenonlongtermoutcomesfollowingcurativeintentresectionofhepatocellularcarcinoma
AT timothympawlik synergisticimpactofalphafetoproteinandtumorburdenonlongtermoutcomesfollowingcurativeintentresectionofhepatocellularcarcinoma
_version_ 1724273971545767936